[go: up one dir, main page]

AU2002214096A1 - Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy - Google Patents

Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy

Info

Publication number
AU2002214096A1
AU2002214096A1 AU2002214096A AU1409602A AU2002214096A1 AU 2002214096 A1 AU2002214096 A1 AU 2002214096A1 AU 2002214096 A AU2002214096 A AU 2002214096A AU 1409602 A AU1409602 A AU 1409602A AU 2002214096 A1 AU2002214096 A1 AU 2002214096A1
Authority
AU
Australia
Prior art keywords
treating
diabetic retinopathy
apoptosis inhibitors
preventing diabetic
pericyte apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214096A
Inventor
Ulriche Denis
Michel Lagarde
Marc Lecomte
Clarisse Paget
Nicolas Wiernsperger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Merck Sante SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
LIPHA SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, LIPHA SAS filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU2002214096A1 publication Critical patent/AU2002214096A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002214096A 2000-10-24 2001-10-24 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy Abandoned AU2002214096A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0013640A FR2815541B1 (en) 2000-10-24 2000-10-24 USE OF PERICYTE APOPTOSIS INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC RETINOPATHY
FR00/13640 2000-10-24
PCT/FR2001/003306 WO2002034201A2 (en) 2000-10-24 2001-10-24 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy

Publications (1)

Publication Number Publication Date
AU2002214096A1 true AU2002214096A1 (en) 2002-05-06

Family

ID=8855696

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214096A Abandoned AU2002214096A1 (en) 2000-10-24 2001-10-24 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy

Country Status (9)

Country Link
US (1) US8119609B2 (en)
EP (2) EP1343491A2 (en)
JP (1) JP4387101B2 (en)
AU (1) AU2002214096A1 (en)
BR (1) BR0114759A (en)
CA (1) CA2428907A1 (en)
FR (1) FR2815541B1 (en)
NO (1) NO20031806D0 (en)
WO (1) WO2002034201A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815541B1 (en) 2000-10-24 2008-02-29 Lipha USE OF PERICYTE APOPTOSIS INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC RETINOPATHY
WO2003061519A2 (en) * 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
JP4991297B2 (en) * 2003-05-22 2012-08-01 キエジ ファルマチェウティチ エッセ・ピ・ア Means for preventing and treating cell death and their biological applications
JP5053836B2 (en) * 2004-04-30 2012-10-24 テラプトシス エス アー Caspase-2 inhibitors and their biological applications
FR2878522B1 (en) 2004-12-01 2008-04-18 Merck Sante Soc Par Actions Si NEW SPECIFIC INHIBITORS OF CASPAS-10
FR2884820B1 (en) * 2005-04-25 2007-07-27 Merck Sante Soc Par Actions Si NEW SPECIFIC INHIBITORS OF CASPASE-10
US8222283B2 (en) 2005-05-17 2012-07-17 Santen Pharmaceutical Co., Ltd. Method for treating a keratoconjunctival disorder
US20070098709A1 (en) * 2005-06-29 2007-05-03 Gaetano Barile Methods for treating and preventing diabetic retinopathy
JP2010507387A (en) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド Novel siRNA and method of using the same
ES2534588T3 (en) * 2007-04-13 2015-04-24 Southern Research Institute Terfenadine as an antiangiogenic agent
WO2008146721A1 (en) * 2007-05-25 2008-12-04 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for age-related macular degeneration
BRPI0817605A2 (en) 2007-10-03 2017-05-09 Quark Pharmaceuticals Inc new siren structures
RU2491066C2 (en) * 2008-02-28 2013-08-27 Сантен Фармасьютикал Ко., Лтд. Preparation for preventing and treating ocular disease accompanied by optic nerve disorder
BRPI0921491A2 (en) * 2008-11-03 2016-07-19 Giuliani Spa therapeutic, dietetic or cosmetic use of compounds with specific anti-apoptotic activity against caspase-3, and compositions containing these compounds
US8410162B2 (en) * 2009-06-15 2013-04-02 Encore Health Llc Choline esters
TN2010000251A1 (en) * 2010-06-03 2011-11-11 Rekik Raouf N-ACETYL-DL-LEUCINE MEDICINAL NEURO AND RETINO PROTECTOR
EP3481395A4 (en) * 2016-07-11 2020-05-13 The Trustees of Columbia University in the City of New York Ocular delivery of cell permeant therapeutics for the treatment of retinal edema
WO2018085565A2 (en) * 2016-11-03 2018-05-11 Helix Biomedix, Inc. Short bioactive peptides blocking activity of advanced glycation end products, compositions, and methods of use
WO2019089993A1 (en) * 2017-11-02 2019-05-09 Living Cell Technologies New Zealand Limited Pericyte protective agents for neurological disorders including neurodegenerative diseases, central nervous system diseases and others
US12257341B2 (en) * 2019-05-31 2025-03-25 Lg Chem, Ltd. Injectable composition containing prodrug of caspase inhibitors, and preparation method therefor
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0789951A (en) * 1993-06-03 1995-04-04 Sterling Winthrop Inc Interleukin-1β convertase inhibitor
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
RU2070010C1 (en) * 1993-08-31 1996-12-10 Эдуард Сергеевич Аветисов Agent for antioxidant protection of eye media and tissues
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
AU1447095A (en) * 1993-12-30 1995-07-17 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
JPH08175993A (en) * 1994-12-21 1996-07-09 Green Cross Corp:The Antioxidant
JPH09278652A (en) 1996-04-05 1997-10-28 Sumitomo Pharmaceut Co Ltd Retinal disease therapeutic agent
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
EP0971743B1 (en) * 1997-04-18 2006-07-12 Fritz Stanislaus Stabilized medicaments containing cysteinyl derivatives
AU8147398A (en) * 1997-07-11 1999-02-08 Ludwig Institute For Cancer Research Non-human pdgf-b-deficient transgenic animals with reduced or non-existent numbers of pericytes
CN1324234A (en) * 1998-09-25 2001-11-28 格利科克斯有限公司 Fructosamine oxidase: antagonists and inhibitors
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
WO2000047218A1 (en) * 1999-02-11 2000-08-17 The Trustees Of The University Of Pennsylvania Regulation of photoreceptor degeneration
DE19915465A1 (en) 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
MXPA01010127A (en) * 1999-04-09 2002-08-20 Cytovia Inc Caspase inhibitors and the use thereof.
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
AU5601300A (en) * 1999-06-09 2000-12-28 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
AU1920501A (en) * 1999-12-03 2001-06-12 Alcon Universal Limited The use of caspase 9 inhibitors to treat ocular neural pathology
JP2004509120A (en) * 2000-09-13 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド Caspase inhibitors and their uses
WO2002030982A2 (en) * 2000-10-13 2002-04-18 Entremed, Inc. Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
FR2815541B1 (en) 2000-10-24 2008-02-29 Lipha USE OF PERICYTE APOPTOSIS INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC RETINOPATHY

Also Published As

Publication number Publication date
US8119609B2 (en) 2012-02-21
WO2002034201A2 (en) 2002-05-02
JP4387101B2 (en) 2009-12-16
FR2815541B1 (en) 2008-02-29
NO20031806D0 (en) 2003-04-23
EP2359840A1 (en) 2011-08-24
FR2815541A1 (en) 2002-04-26
WO2002034201A3 (en) 2003-03-27
US20030216290A1 (en) 2003-11-20
CA2428907A1 (en) 2002-05-02
JP2004512287A (en) 2004-04-22
BR0114759A (en) 2003-10-07
EP1343491A2 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
AU2002214096A1 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
AU2002361846A1 (en) Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
PL365520A1 (en) Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
AU2001282886A1 (en) Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AU2002367172A1 (en) 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2001274817A1 (en) Agents that modulate dna-pk activity and methods of use thereof
AU2208401A (en) Inhibitors of complement activation, their preparation and use
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
AU5463099A (en) Inhibitors of redox signaling and methods of using same
AU2002232400A1 (en) Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002227123A1 (en) Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
AU3270301A (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
AU2001232060A1 (en) Use of cyp1b1 inhibitors for treating cancer
AU2003249930A1 (en) Proteaseome inhibitors for the treatment of herpesviridae infected individuals
AU2001262939A1 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
AU2001280093A1 (en) Method for the prevention and treatment of retinopathy
EE200300057A (en) Ingredients for the prevention and treatment of cancer
PL356102A1 (en) 15-hydroxyeicosatetraenoic acid-related compounds and methods of use

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted